Breast cancer in this cohort has a higher frequency of grade 3 (Yap et al., 2018) and larger tumour size compared to non-NF1 breast cancers (Uusitalo et al., 2017), with later presentations resulting in a poorer prognosis (Sheridan et al., 2014). This evidence concerns the gene NF1 and breast cancer.